Congenica secures US$50 million Series C funding round

KUALA LUMPUR, Nov 9 -- Digital health company, Congenica has announced the completion of its Series C funding round, raising US$50 million/£39 million. (US$1 = RM4.12)

The round was co-led by Tencent and Legal & General and included other new investors Xeraya, Puhua Capital and IDO Investments with existing investors Parkwalk, Cambridge Innovation Capital and Downing.

The global nature of its important financing round brings new strategic and geographic capabilities that will further advance Congenica’s existing global footprint, according to a statement.

A pioneer in genomic analysis, Congenica has established a diverse, global customer-base of hospitals, diagnostic laboratories, academic medical centres and pharmaceutical companies.

The new funding is aimed at accelerating international market development and driving further expansion of Congenica’s product platform into somatic cancer, wellness and through partnerships with pharmaceutical companies.

Furthermore, the company will deliver advanced capabilities including the ability to integrate with existing electronic health systems and deliver fully automated interpretation capability.

By integrating its software into existing systems and infrastructure, and further developing ground-breaking machine learning capabilities, Congenica is building a future where personalised decisions and treatments, guided by genomic information, can be routinely used to transform the health and wellness of individuals worldwide.

For details, visit www.congenica.com.

-- BERNAMA